Jinhai Med Tech (02225) surged more than 21% during Tuesday's trading session, extending its cumulative gain to nearly 60% since being included in the Stock Connect program. As of the time of writing, the stock was up 16.93% at HK$6.70, with turnover reaching HK$92.47 million.

The company was recently added to the Hong Kong Stock Connect list, opening the compliance buying channel for southbound capital and further enhancing the stock's liquidity. In the first half of 2026, revenue from minimally invasive surgical solutions, medical products, and related service fees climbed to 74.73% of total revenue. Following the strong growth in medical device sales in 2025, this segment's revenue surged 301.5% year-on-year to S$25.427 million, demonstrating robust sustainable growth momentum.

The explosive growth in the minimally invasive surgical solutions business has validated the company's solid capabilities in product R&D and manufacturing. Notably, this performance growth is underpinned by the company's long-term commitment and continuous breakthroughs in technology R&D. According to company information, Jinhai Med Tech's product portfolio now covers a range of innovative offerings, including 4K ultra-high-definition endoscopy systems, 3D and glasses-free 3D image processing systems, 4K fluorescence and multispectral ultra-high-definition endoscopy systems, as well as 8K endoscopy systems. The portfolio extends to supporting auxiliary equipment, forming a closed-loop industry chain spanning R&D, production, sales, and service.